Impax Laboratories Inc

Impax Laboratories — FY2016 Earnings Presentation

24 slides from Impax Laboratories's earnings presentation, Mar 1, 2017

  1. Slide 1: Fourth Quarter and Full Year 2016 Results

    1 Fourth Quarter and Full Year 2016 Results March 1, 2017

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and

  3. Slide 3: Agenda

    3 Agenda Business Update  Kevin Buchi – Interim President & Chief Executive Officer Financial Review  Bryan Reasons – Senior Vice President, Chief Financial Officer Additional Participants for Q&A Session  Doug Boothe – President Impax Generics  Michael Nestor – President Impax Specialty Pharma

  4. Slide 4: Business Update

    4 Business Update Kevin Buchi Interim President & Chief Executive Officer

  5. Slide 5: Summary of 2016 and Generic Industry Challenges

    5  Increased rate of ANDA approvals by FDA  Consolidation of payers and customers  Aggressive competition and pricing activities; impacted our 2016 results  Generic division pricing declined ~22%  Excluding diclofenac sodium gel and metaxalone; pricing declined ~12% Generic Industry Challenges…

  6. Slide 6: Generics Business Highlights

    6  Expanded production/supply  Enhanced greater awareness  The “Go To Choice”  Significantly expanded preferred drug list status  CVS agreement  2016 revenue of $92MM; up 139% over 2015 Generics Business Highlights IMS NPA Weekly Feb. 17, 2017 0% 5% 10% 15% 20% 25% 30% Epinephrine Auto-Injecto

  7. Slide 7: Delivering Solid Growth Across Specialty Portfolio

    7  Redefined clinical messaging related to formulation  Simplified dose conversion guidance for general neurologists  Launched myRytary Patient Support Program www.myrytary.com  74% revenue growth and 114% script growth in 2016 (a) Delivering Solid Growth Across Specialty Portfolio  Emphasis on

  8. Slide 8: Investing to Expand Pipeline Opportunities

    8 Investing to Expand Pipeline Opportunities Source of sales data: IMS NSP Dec 2016; *U.S. Brand/Generic market sales; Pipeline data as of Feb 24, 2017 Generic R&D 16 14 7 6 Pending at FDA $14B Under Development $10B Solid Oral Dose Alternative Dose 23 20 # of Potential Products FTF or FTM 8 17 Spec

  9. Slide 9: Leveraging Our Strengths and Focusing on Opportunities for Growth

    9 Leveraging Our Strengths and Focusing on Opportunities for Growth  Continue focus on sustainable quality and compliance programs  Select the right products for internal and partnership development  Develop, file and launch on time and capitalize on market opportunities  Ensure effective and co

  10. Slide 10: Financial Review

    10 Financial Review Bryan Reasons Senior Vice President, Chief Financial Officer

  11. Slide 11: Consolidated 4Q & FY 2016 Results

    11 Consolidated 4Q & FY 2016 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results ($ millions, expect per share data) 4Q 2016 4Q 2015 FY 2016 FY 2015 Revenues $198 $282 $824 $860 Gross (Loss) Profit $(161) $115 $(151) $352 Gross Margin

  12. Slide 12: Non-Cash Intangible Asset Impairment Charges

    12 $ millions 4Q 2016 FY 2016 Tower Holdings Acquisition  Currently marketed portfolio $175 $177  In-process R&D $20 $46  Other --- $8 Teva Transaction  Currently marketed portfolio $54 $302  In-process R&D $4 $7 Other  Currently marketed portfolio $1 $1 Total non-cash impairment $254 $542 Not

  13. Slide 13: Generic Division 4Q & FY 2016 Results

    13 Generic Division 4Q & FY 2016 Results ($ millions) 4Q 2016 4Q 2015 FY 2016 FY 2015 Revenues $139 $227 $606 $711 Gross (Loss) Profit $(176) $76 $(275) $261 Gross Margin (127%) 34% (45%) 37% Adjusted Gross Profit $46 $92 $238 $303 Gross Margin 33% 41% 39% 43% (Loss) Income from Operations $(212) $4

  14. Slide 14: Specialty Pharma Division 4Q & FY 2016 Results

    14 Specialty Pharma Division 4Q & FY 2016 Results ($ millions) 4Q 2016 4Q 2015 FY 2016 FY 2015 Revenues $59 $55 $218 $150 Gross Profit $15 $38 $124 $92 Gross Margin 26% 70% 57% 61% Adjusted Gross Profit $47 $46 $174 $121 Gross Margin 79% 84% 80% 81% (Loss) Income from Operations $(17) $19 $12 $19 Ad

  15. Slide 15: Capitalization as of December 31, 2016

    15 Capitalization as of December 31, 2016 Capitalization ($ millions) 4Q 2016 Cash and Cash Equivalents $180 2022 Convertible Senior Notes $600 Term Loan $395 Total Debt $995 Net Debt $815 Net Debt to Adjusted EBITDA 4.1X Excess Free Cash Flow Primarily Targeted for Debt Reduction Feb. 28, 2017 – ma

  16. Slide 16: 2017 Outlook

    16 The Company’s full year 2017 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The following statements are forward-looking, and actual result

  17. Slide 17: 2017 Assumptions

    17 2017 Assumptions Generic Division  Aggressive competition and pricing activities expected to continue  Pricing erosion in the high single to low double digit range  Minimal contribution from approved/tentatively approved products expected to launch throughout 2017  Generic Vytorin® (tentative

  18. Slide 18: 2017 Financial Guidance Summary

    18 2017 Financial Guidance Summary Guidance Adjusted Gross Margin as a % of Revenues  47% to 49% R&D & Patent Litigation Expense  $90MM to $95MM Selling, General & Administrative Expense  $190MM to $195MM Adjusted Interest Expense  $30MM Tax Rate  34% to 35% Capital Expenditures  $25MM to $30M

  19. Slide 19: Q&A

    19 Q&A

  20. Slide 20: ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities

    20 ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities Source of sales data: IMS NPS Dec 2016; Pipeline data as of Feb 24, 2016; TA = tentative approval 1 Launched authorized generic in April 2016 2 Assuming final FDA approval, earliest potential launch date/timing base

  21. Slide 21: GAAP to Adjusted Results Reconciliation

    21 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from operations. (Unaudited, amounts in thousands) Refer

  22. Slide 22: GAAP to Adjusted Net Income Reconciliation

    22 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net (loss) income to adjusted net income. (Unaudited, amounts in thousands, except per share and per share data) Refer to the Fourth Quarter 2016 Earnings Release for an explanation of adjusted items. The sum of th

  23. Slide 23: Generic Division GAAP to Adjusted Results Reconciliation

    23 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amo

  24. Slide 24: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    24 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from oper

Impax Laboratories — FY2016 Earnings Presentation on 6ix